Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine in the treatment of ADHD
IRCT201312181556N55Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of agomelatine in attention deficit hyperactivity disorder (ADHD), sponsored by Tehran University of Medical Sciences. Started Jan 2014; status: completed.
02
Drugs
agomelatine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on IRCT201312181556N55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201312181556N55.